• Global functional water market forecast to reach $158.28 billion in 2023
• Through its wholly owned subsidiary, Naturo Group, BevCanna offers full line of alkaline and plant-based mineral-infused waters within functional water market
• North American distribution network expanded significantly in recent weeks via agreements with Koyo Foods throughout Ontario and Quebec and Benefit Brand Management in populous U.S. cities
• In response to consumer demand for more options, BevCanna is launching new line of multi-packs for sale throughout Canada

There is always something on the market that health-conscious individuals crave to put in their body, whether it has anecdotal or clinical rationale behind it. Amid healthier trends away from sugary drinks, functional water continues to grow in popularity, and BevCanna Enterprises’ (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Naturo Group is there to provide, offering its “TRACE” lineup of alkaline and mineral-infused water products sourced from the company’s pristine alkaline spring water aquifer in British Columbia. On the back of two new distribution deals, the North American retail network for TRACE products just got significantly bigger, for which the company responded with a new multi-pack options for consumers. Alkaline waters, those with a pH between 7.1 – 9.9, are believed to deliver many health benefits, including boosting immunity. Mineral-infused water goes by several names, including black water, mineralized fulvic and humic spring water, and ionic mineral water and contains dozens of naturally occurring minerals essential to health. Proponents contest that there is no scientific evidence that either type of water conclusively helps the body, but the global functional water market forecast to reach $158.28 billion in 2023 tells a different story about what consumers think (https://ibn.fm/aDRAr). Ahead of the deals, BevCanna’s distribution network already spanned over 3,000 retail locations and online at www.mytracewellness.com, giving TRACE a strong start to compete for market share. Early in June, Naturo struck a deal with Koyo Foods, one of the largest health food distributors in Eastern Canada, to add the TRACE line to its portfolio of reputable brands, like Earths Own, Thirsty Buddha, and Gusta Artisanal Vegan, to its retailers across Ontario and Quebec. The response was immediate, with Koyo confirming that “a number of retailers” had already placed orders for TRACE (https://ibn.fm/GZGio). In the U.S., BevCanna inked a distribution agreement with Benefit Brand Management, a leader wholesaler of natural products. This new pact is starting out with Benefit Brand placing TRACE products at an array of U.S. retailers, including independent natural and specialty retailers and big box retailers, starting in New York, Chicago and select cities in California (https://ibn.fm/HFUne). Currently, all the TRACE waters are sold in individual plastic and/or aluminum cans ranging in size from 355 mL to 4 L. In response to consumer demand for take-home and value-priced options, BevCanna is launching new TRACE multi-packs in national retailers across Canada. The increased distribution and new packaging options speak to the success of BevCanna’s expert sales team, led by VP of Sales and Insights Raffael Kapusty and VP of Sales and Sales Operations Bill Niarchos. Kapusty and Niarchos are seasoned consumer package goods veterans that were instrumental in signing the Koyo and Benefit Brand deals, amongst others that are spreading TRACE products across the continent. “We’re pleased that consumer demand for the TRACE line of alkaline and mineral-infused water products has taken off so quickly,” said Melise Panetta, President of BevCanna. “The addition of the new multi-pack options reflects the very positive response we’ve seen in the Canadian marketplace to our wellness-focused range of products,” she added. BevCanna manufactures TRACE products in Canada from its state-of-the-art 40,000 square foot HACCP certified facility. It also performs white label production services, which are expected to generate at least $2.4 million in revenue based upon the first three contracts, a nice complement to corporate coffers while TRACE distribution continues to expand. The company still has plenty of headroom to keep growing considering the facility has capacity of 210 million bottles per annum. For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• According to CEO Evan Gappelberg, Nextech is the only diversified small-cap company participating in the rapidly growing digital transformation
• The company is ideally positioned to capitalize on the rapid market adoption environment accompanying the ongoing evolution of AR-led technology
• A recently released report by Facebook shows that a majority of companies will adopt AR and VR technologies in the coming years and that spending on these technologies will increase sixfold by 2024
• This report augurs well for Nextech’s operations as the company, which already has existing AR solutions, is driving market-wide AR-adoption

As the business world undergoes a paradigm shift forcing more and more companies to embrace and implement digital transformation, technology juggernauts are leading the way by offering cloud computing, streaming, e-commerce, networking, video conferencing, augmented reality (“AR”), and virtual reality (“VR”) services and infrastructure. But this role is not the reserve of such behemoths, especially because Nextech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), a diversified small-cap company, is participating in the rapidly growing digital transformation. The company, which is one of the leaders in the rapidly growing AR industry, is capitalizing on the fact that the major catalysts for AR and VR adoption, i.e., the 5G network whose installation is ongoing in multiple countries around the world and AR-capable consumer wearable devices that hitting the market, are already in place. In a presentation to investors during the Virtual Investor Conferences, Nextech Founder & CEO Evan Gappelberg noted that the world is currently experiencing the fourth industrial revolution, which is prompting technological evolution at a pace never before seen (https://ibn.fm/NqqJZ). “This evolution is being led by AR, AI, Internet of Things (“IoT”), edge computing and the 5G network, all of which are converging and becoming increasingly ubiquitous for training, e-commerce, advertising, and entertainment,” the presentation reads. “This convergence is stimulating a rapid market adoption environment similar to the internet in the 1990s, driving the creation of billion-dollar industries almost overnight, a market Nextech is uniquely positioned to capitalize on.” In a new volume of its quarterly Hello Future report series (https://ibn.fm/EYpNB), Facebook corroborates Evan’s sentiments. The report, which augurs well for Nextech’s operations, notes that the importance of AR and VR in people’s everyday lives will grow in the near future; people are welcoming AR into their lives – 78% of people around the world say AR is a fun way to interact with brands and 74% believe AR can bridge the gap between online and offline. It also notes that 75% of business leaders expect to be using AR or VR by 2023 and projects that 2020’s spending on AR and VR will grow sixfold by 2024. In its analysis, the report states that AR and VR could revolutionize how people engage with brands and how brands engage with people by bridging the gap between online and offline shopping – it allows customers to try, explore, and digitally overlay products into real environments. And that AR and VR are making the world more efficient and equal, thanks to their impact on multiple sectors, including education and medicine. “The appeal is definitely growing in multiple markets across the globe. This is a clear indication that unique and interactive tech platforms will play a big role in the future and provide businesses with a plethora of exciting ways to interact with their customers,” observes a Digital Information World (“DIW”) article discussing the Facebook report (https://ibn.fm/66IDt). Although the statement by DIW tells of the future, Nextech, through its existing unique and interactive solutions, already plays a key role and is providing businesses, students, event organizers, event attendees, and instructors with a plethora of exciting ways to interact. For instance, multiple organizers have selected its Virtual Experience Platform (“VXP”) to host virtual events, while Ryerson University, Carnegie Mellon University, and other higher education institutions are already using its newly launched EdTechX platform (https://ibn.fm/s2mHQ). Moreover, the company offers AR-based solutions for e-commerce. While the DIW article regards AR and VR technologies as being in their infancy, Nextech is already participating in digital transformation by driving market-wide AR adoption. What’s more, its solutions are benefiting its clients by increasing measurable ROI, brand loyalty, online sales, and product awareness. For more information, visit the company’s website at www.NextechAR.com. NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

• Asia Broadband, an experienced producer of precious metals, is in the process of adding key gold mine property acquisitions in Mexico
• The company’s approach to metals sales to primarily Asian markets includes development of a cryptocurrency exchange with a token backed by its gold holdings
• Asia Broadband’s AABBG token will be traceable through the proprietary exchange for currencies such as Bitcoin, Ethereum and Litecoin, and will also be able to acquire value on principles of limited production and rising demand
• The company recently reported its enthusiasm over preliminary assay results on rocks taken at random throughout a mine in Nayarit that is subject to an LOI
• Asia Broadband is also working to increase shareholder value through agreements to retire some third-party shares

Precious metals resource holder and cryptocurrency developer Asia Broadband (OTC: AABB) is pressing forward with its efforts to acquire new gold reserves in Mexico, and announced May 25 that one of the mines subject to its letter of intent (“LOI”) has produced high-grade rock sample assay results from specimens collected at random throughout the property when due diligence procedures began. The preliminary report on the sample assay from the Acaponeta-Bonanza project increases the company’s hopes of obtaining high-grade mineralization values and vein concentrations throughout the property once an acquisition agreement is finalized. In addition, Las Vegas-based Asia Broadband has $30 million in gold held in reserve to provide backing to its cryptocurrency, which it launched in March as the AABBG token. The company has been assessing several gold mine projects since the beginning of the year, and has issued LOIs for mines and processing facilities in the states of Jalisco and Nayarit with a view of adding to its gold holdings under its mine-to-token strategy (https://ibn.fm/eVRYz). The Acaponeta project in Nayarit has two mine sites, existing infrastructure and a 200 ton-per-day processing facility located in a prolific mining region. The random rock samples included findings of 10.4 grams per ton (g/t), 8.9 (g/t) and 6.8 (g/t) of gold, according to the May 25 announcement (https://ibn.fm/cXn7R). Asia Broadband anticipates the potential acquisition will “expeditiously advance AABB into production and an expansion program,” according to the announcement. The company is intent on establishing a proprietary cryptocurrency exchange, which it expects to test in August and then launch in September. The company has been completing its cold wallet, web interfaces, transaction fee mechanism, trade platform and reporting system. Sales of the AABBG token have netted about $1.5 million in cryptocurrencies since March. The token’s value will be tethered to the existing price of one-tenth (0.1) gram of gold but the exchange will allow the token to achieve price appreciation beyond the minimum spot price supported by the gold reserve (https://ibn.fm/KYNPu), according to demand. The exchange will primarily make it possible for AABB Wallet users to complete quick two-way exchanges of their tokens for major cryptocurrencies such as Bitcoin, Ethereum and Litecoin. In a bid to increase shareholder value, the company completed agreements with some third parties to retire their shares for a return of 107 million restricted common shares to the company treasury, according to an announcement May 27 (https://ibn.fm/JZXUu). Asia Broadband expects to retire additional shares in the coming weeks to continue to build shareholder value. The company’s executive management team states Asia Broadband is in a highly liquid financial position to self-fund and is prepared to rapidly advance its business segments focused on mining and crypto creation (https://ibn.fm/BmTH0). It recorded an annual gross profit of $16.8 million at the end of the 2020 fiscal year (https://ibn.fm/S1T7O). For more information, visit the company’s website at www.AsiaBroadbandInc.com. NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• Earlier this year, Grapefruit was approached by a Canadian cannabis company about a potential acquisition
• A series of events have delayed the process
• Final decisions, details should be discussed in the next 30–60 days

Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed, California-based cannabis company, is providing clarification regarding its previously announced potential acquisition transaction by a Canadian cannabis company (https://ibn.fm/mymt2). Earlier this year, Grapefruit announces that it had been approached by a Canadian cannabis company to enter into discussions concerning a potential acquisition transaction (https://ibn.fm/LShI3). At the time, Grapefruit CEO Bradley J. Yourist noted that “Grapefruit is not surprised to be approached concerning a potential acquisition, in light of the company’s recent disclosure concerning its 714% year-over-year revenue increase; the public reaction to the company’s patented, disruptive Hourglass(TM) THC/cannabinoid delivery cream; and recent announcements by U.S. Senate Majority Leader Chuck Schumer concerning prioritization of the federal legalization of cannabis by de-scheduling THC.” Following that initial announcement, Grapefruit issued a series of follow-up announcements noting further progress of the potential acquisition, including the development of a memorandum of understanding (“MOU”) that sets forth terms under which the parties could enter into a joint venture to jointly manufacture, distribute and market Grapefruit’s products (https://ibn.fm/o39cc) as well as an announcement that the Canadian partner had scheduled a special shareholder’s meeting to consider the proposed joint venture and other corporate matters (https://ibn.fm/lT09w). At the shareholder meeting, the Canadian partner’s shareholders elected new directors and approved the acquisition of a Canadian-based hemp cultivator. Those actions triggered a change in control of the Canadian partner; as a result, the company had to submit new filings to the Canadian Stock Exchange and the formal joint venture agreement and further acquisition discussions were postponed pending acceptance of the filing by the CSE, which the Canadian partner expects in the very near future. “While Grapefruit was, of course, disappointed by the delays occasioned by our counterpart’s corporate action (which were in progress before our discussions commenced), we believe it was in the best long-term interests of Grapefruit and its shareholders to accept a pause while the Canadian partner concluded its corporate actions,” Yourist said. “Now we move forward. “As we have stated before, a joint venture may precede without precluding an acquisition. Execution of the MOU moved the entire process forward as we now more clearly understand each other’s overall goals and priorities as well as the capital requirements and legal, regulatory and logistical challenges of finalizing a joint venture and/or an acquisition,” Yourist continued. “We expect to bring the process forward to the point of making a decision in the next 30–60 days. Once again, that being said, we wish to emphasize that the discussions reported here, although substantive and largely positive, remain preliminary in nature and may be terminated at any time. Grapefruit will update the public as necessary on any material joint venture or acquisition developments as events proceed.” Grapefruit holds California permits and licenses to both manufacture and distribute cannabis products in the Golden State. The company’s extraction laboratory and manufacturing and distribution facilities are located in the industry-recognized Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, located on the extension of North Canyon Road, approximately 14 miles north of downtown Palm Springs. Grapefruit’s flagship product — Hourglass time-release delivery cream — features cutting-edge science and technology that solves the age-old problem of THC and other cannabinoids not being easily absorbed through the skin. The topical cream uses patented microsized particles to slowly deliver THC and a wide range of cannabinoids through skin topical administration. No other topical cream product on the market provides users with the holistic benefits of the range of cannabinoids found in Hourglass. To find out more about the company and its game-changing Hourglass time-release cannabinoid delivery cream, please visit www.GrapefruitBlvd.com. NOTE TO INVESTORS: The latest news and updates relating to GPFT are available in the company’s newsroom at https://ibn.fm/GPFT

• Ideanomics completed the acquisition of US Hybrid, a manufacturer and distributor of electric powertrain parts and fuel cell engines for medium and heavy-duty vehicles
• IDEX paid an aggregate purchase price of $50 million in cash and stock considerations
• The acquisition marked IDEX’s entry into the burgeoning EV powertrain market, which is expected to grow at a CAGR of 16% from 2020 to 2027
• The growth is due to several favorable factors that also bode well for the operations of IDEX and US Hybrid
• Ideanomics also announced that US Hybrid had received orders from Global Environment Products (“GEP”) for a fleet of all-electric street sweepers

Ideanomics (NASDAQ: IDEX) entered 2021 with the expectation that it would be yet another growth year. The company, which started the year by completing the acquisition of Wireless Advanced Vehicle Electrification (“WAVE”) and Timios, continued seeking new investments and acquisitions in revenue-based opportunities that would complement its existing operations segmented into two divisions – Ideanomics Mobility, dealing with electric vehicle (“EV”) business, and Ideanomics Capital, focusing on fintech. Early this month, Ideanomics added yet another company to its growing list of wholly owned subsidiaries when it completed the acquisition of 100% of privately held US Hybrid, a manufacturer and seller of electric powertrain parts and fuel cell engines for medium and heavy-duty municipality vehicles, commercial trucks, buses, and specialty cars (https://ibn.fm/YiciM). Expected to bring synergistic benefits to the various companies under the Ideanomics Mobility umbrella, the acquisition of US Hybrid is on the heels of a report by Market Research Future (“MRFR”), which anticipates the EV powertrain market to grow at a 16% CAGR between 2020 and 2027, reaching $135 billion (https://ibn.fm/pwI00). This projected growth is buoyed by several favorable factors that also bode well for the operations of both IDEX and US Hybrid. These include:

• An increase in the demand, production, and sales of EVs
• Improving EV infrastructure in multiple countries
• Stringent government regulations
• The burgeoning need for energy-efficient drivetrain systems
• The increasing adoption of electric powertrains in commercial vehicles
• Growing demand for electric powertrains in city trucks

Perhaps indicative of the burgeoning need and demand for energy-efficient electric drivetrain systems and cars, in line with the MRFR report, Ideanomics also announced that US Hybrid had received orders from Global Environment Products (“GEP”) for a fleet of all-electric street sweepers to deploy in various cities in the US and around the world. GEP, a manufacturer of specialized, purpose-built, heavy-duty, and reliable street cleaning equipment, and US Hybrid already have an existing partnership that has led to the delivery of many clean street sweepers to clients in the US and Japan. And although the current order is simply an extension of this partnership, it is expected to add more than $1 million in revenue to US Hybrid’s balance sheet for the current financial year. Each new, all-electric street sweeper will feature one 120-kW traction motor and lithium-ion batteries charged via an AC 20kW, SAE J1772-compliant charging system. Further, each sweeper is expected to save approximately 89 metric tons of carbon emission over the vehicle’s lifetime, equivalent to taking a total of 19 cars off the road for a whole year. “We welcome Dr. [Gordon Abas] Goodarzi and his entire team to Ideanomics and are confident they will bring tremendous knowledge, innovation, and value to the company in addition to their synergistic alignment with many of our existing subsidiary brands,” said IDEX CEO Alf Poor. “I look forward to the accelerated commercialization and innovation US Hybrid will bring to Ideanomics’ ecosystem. It will benefit businesses, communities around the world, and more importantly, our planet.” On his part, Dr. Goodarzi, Ph.D., PE, the CEO of US Hybrid, said: “Ideanomics has emerged as a true powerhouse in the commercial EV sector with a synergistic ecosystem of technologies and solutions that covers the entire value chain of electrification. We look forward to leveraging that strength going forward.” For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• WTER 2020 FY revenues make company largest alkaline water company in the U.S.
• In addition, the brand is one of the top-10 largest enhanced water brands in the country
• Research shows that Alkaline88 has the greatest brand loyalty among alkaline water drinkers

With its most recent financial report, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) is now the largest independent alkaline water company in the nation, having reported 2020 FY revenue of $41.1 million, which represents a 28% increase year over year. Leading the pack is an impressive accomplishment, especially when the market is projected to reach $1 billion in 2022 (https://ibn.fm/wjAhh). WTER has shown consistent growth since the release of its flagship product: Alkaline88(R). Alkaline88 ionized water contains only two ingredients — water and Pink Himalayan rock salt — and has built a reputation for superior hydration with a perfect 8.8 pH balance. The brand was formulated to offer a smooth taste that encourages consumers to drink more and fully hydrate, key factors in maintaining health and wellness. Alkaline88 is now available in more than 75,000 retail stores nationwide, and in addition to being number one in the indie alkaline water space, the brand has captured a prestigious spot as one of the top-10 largest enhanced water brands in the country as well. As per Nielsen data, the brand is the only top-10, nonflavored, value-added water brand that has consistently grown double digits in both units and dollar volume every four-week period since the end of 2019. In addition, research indicates that Alkaline88 has the greatest brand loyalty among alkaline water drinkers. “The brand awareness and newfound loyalty during COVID-19 was best exemplified by independent data that showed 31% of the people who drank Alkaline88 during the 52-week period ended March 6, 2021, were first-time buyers,” reported a recent article (https://ibn.fm/s1OFI). The same research showed that 47% of purchases of Alkaline88 in the last year are from consumers who have bought it four or more times. “Part of the reason for the loyalty likely has to do with the social culture of The Alkaline Water Co.,” the article continued. “Millennials and younger generations are passionate about ethos and factor that into decision making about purchases. The company adheres to the strictest industry guidelines set forth by individual states, FDA, EPA and International Bottled Water Association. It has retooled its ionization system to use less water and electricity and was the first national company in the industry to offer eco-friendly aluminum packaging options.” In addition to its flagship Alkaline88 brand, the company launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique naturally flavored options. Additionally, in 2020, the company announced its A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested hemp extract salves, balms, lotions, essential oils and bath salts, powder packs, oil tinctures, capsules and gummies. For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes.
• Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process.
• Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types

Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches and technology are playing important roles in increasing the chances of a drug’s success from the outset—a fact not lost on stakeholders when making investment decisions (https://ibn.fm/t4SkS). Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes. Looking to give oncology drug developers an upper hand, TumorGenesis, a subsidiary of Predictive Oncology (NASDAQ: POAI), has partnered with Swedish cell culture system company Cellevate AB for the purpose of combining TumorGenesis’ medias with Cellevate’s high engineered matrix materials (https://ibn.fm/ftoee). More specifically, the collaboration will involve using TumorGenesis expertise in cancer cell culture growth media in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer, the fifth most deadly type of cancer in women in the U.S. and leading cause of death amongst cancers of the female reproductive system (https://ibn.fm/0Ukpr). The goal is to bring researchers the next generation of tools for hard-to-treat diseases. Armed with new tech, drug developers can aim to avoid early mistakes related to selecting the wrong target based on cancer cell lines. Missteps contribute to the already exorbitant cost of drug development, a figure estimated at $2.6 billion by Tufts Center for the Study of Drug Development (https://ibn.fm/gAxOG). Cells in Cellevate’s nanofibers networks are allowed to proliferate and interact with other cells in three dimensions (“3D”), in contrast to the monolayer cultures seen on conventional two-dimensional (“2D”) surfaces. TumorGenesis technology facilitates ex-vivo (outside the body) ovarian cancer cell and tumor growth that mimics that of the patient. The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before. “This combination will give researchers the ability to grow ovarian cancer tissues in a 3D matrix support system with the right media for the right ovarian cancer cell types,” commented Richard Gabriel, SVP of Research & Development at Predictive Oncology. Parent to a family of companies, Predictive Oncology is focused on applying data and artificial intelligence to cancer personalized medicine and drug discovery. “By combining the strength and expertise of our organizations we believe that we can bring something truly unique and valuable to the market,” commented Cellevate CEO Maximilian Ottosson. POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow. For more information, visit the company’s website at www.Predictive-Oncology.com. NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

Date: June 22-24, 2021 Virtual Event The 11th Annual Medical Device Strategic Pricing & Accounts Conference is being held from June 22-24, 2021, at Q1 Productions dynamic virtual platform. Companies, representatives, and professionals from the Medtech industry are invited to attend this virtual event. Operating since 2006, Q1 Productions specializes in delivering educational programming through its curated conferences and research-based events. The official sponsor of this conference is PROS, an AI-powered commerce platform offering personalized customer experience solutions to MedTech companies, in addition to networking sponsor Charles River and Associates, and bronze sponsor ZS Pharma. The 3-day virtual conference will witness keynote panel discussions, fireside chats, and group discussions where participants will get in-depth insights into the industry practices to regulate and control the pricing of the medical device landscape. The conference has 3 major modules distributed over three days and eminent MedTech industry veterans will facilitate and offer their invaluable opinions on the various topics outlined in the agenda of the conference. Some important topics and discussions covered in the Conference include:

• Assessment of policy changes for the purchase and pricing of medical devices during the Biden administration
• Developing a harmonious value proposition between the traditional practices as well as the evolving health care market
• Roadblocks encountered due to the impact of the pandemic that has increased the need for virtual interactions
• Growth of the Medtech sector during the pandemic
• Use of AI for a better buying and selling experience of the consumer
• Building a culture of ethics and compliance parameters that must be considered for contract negotiations
• Discussions with GPOs, IDNs, and manufacturers, to prepare pricing and enterprise sales teams for upcoming healthcare challenges
• Addressing the impact of outpatient center needs on hospital revenue generation and the impact on supplier & provider processes
• Contemporary improvements to the Medtech pricing model
• Impact on performance-based pricing due to COVID-19

The conference modules cover all aspects of medical device strategic pricing serving as a complete Medtech pricing learning guide for newbies and established companies in the medical device segment. For more details regarding the event, please visit https://ibn.fm/8X32c

• Knightscope Inc. has seen a 46% drop in reported crime at one location and has operated over 1,000,000 hours of service for its autonomous security robots nationwide
• The versatility of the robots have seen their deployment in various areas such as airports, manufacturing plants, hospitals, stadiums, residential and commercial properties
• Recently, the Grand Sierra Resort and Casino adopted Knightscope’s K5 robot, aptly named “Jackbot,” to complement the facility’s existing security team
• This marks Knightscope’s growing client base that only confirms what the robots can do while working towards the company’s mission of a safer country

Knightscope’s mission, since its inception back in 2013, has been to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country. Driven by technology and innovation, the company has rolled out three products and overseen a 46% decrease in reported crime in one particular location and has operated well in excess of 1 million hours across the country. The company currently holds contracts across 6 U.S. time zones (https://ibn.fm/zKXC5). So far, Knightscope’s products operate in various areas of application including, but not limited to airports, manufacturing plants, hospitals, stadiums, residential and commercial properties, and numerous corporate campuses. In a client catalogue that seems to be steadily growing given the value proposition that Knightscope offers, the latest name therein has been the Grand Sierra Resort and Casino in Reno, Nevada (https://ibn.fm/qvloP). The resort features close to 2,000 hotel rooms and suites and a 100,000 square feet casino floor, the largest in northern Nevada (https://ibn.fm/yW2Ll). Additionally, it offers a broad range of dining, nightlife and entertainment options. Its move to adopt a Knightscope ASR to cover the massive facility is a testament to what Knightscope products can do, how dependable they are, and how much value they bring to the table. Knightscope is known for developing Autonomous Security Robot (“ASR”) products that feature self-driving technology, artificial intelligence (“AI”) and robotics. Its primary offerings are the K1 stationary machine, the K3 indoor machines and the K5 outdoor machine. All these products are developed from the ground up at Knightscope’s Mountain View, California facility. The Grand Sierra Resort and Casino went with the Knightscope K5 ASR that features two-way communication, 360-degree view cameras, an emergency call button and thermal imaging. Named “Jackbot,” this ASR is meant to work in tandem with the facility’s physical security team and add a layer of security to patrols within the space. It will serve as an extra set of eyes and ears and a much-needed added level of protection for the facility. There have been concerns regarding the safety of security jobs from automation, and with good reason. With innovations and offerings such as Knightscope’s K1, K3 and K5, it is easy for one to see how, ultimately, they could take over all security jobs. That is, however, not the case. In an interview with Knightscope’s CEO, William Santana Li, he noted that “The robots are intended to be eyes and ears for the humans, not a one to one replacement (https://ibn.fm/Elwaj).” This is further affirmed by the Grand Sierra Resort and Casino’s adoption and use of the robots for its security needs. The facility’s K5 “Jackbot” is meant to allow officers to see and hear what is going on, communicate with staff and customers through the robot and, when needed, dispatch additional officers. Jackbot is not a replacement but rather a tool that complements the facility’s security personnel, just as Knightscope intended it to be. As Knightscope’s ASRs continue to log more hours in the field, more data is being collected, facilitating the further improvement of the robots and the value they offer. In addition, establishments such as the Grand Sierra Resort and Casino see the value of the robots, consequently integrating them into their spaces. As such, it is only a matter of time before they become more mainstream, get to serve in more diverse areas and contribute to Knightscope Inc.’s mission of making the United States of America the safest nation in the world. For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Brain cancer drug developer CNS Pharmaceuticals is actively enrolling patients for a potentially pivotal Phase 2 trial of the company’s lead drug candidate, Berubicin, a promising candidate for treating a devastating condition
• CNS’s focus has been on developing a means of combating glioblastoma, a fatal, generally incurable class of brain cancers that are aggressive and recurrent amid current surgical and chemotherapy interventions
• One patient from the Phase 1 trial of Berubicin 15 years ago remains cancer-free, as assessed in November, despite glioblastoma’s reputation for proving fatal generally within about 15 months of diagnosis
• CNS recently announced it will be included in the Russell 2000 Index of small-cap companies for the coming year, effective June 25, which it expects to boost its visibility among investors

As novel biopharmaceutical CNS Pharmaceuticals (NASDAQ: CNSP) approaches its annual meeting of stockholders scheduled for June 28, the company is enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of the company’s lead drug candidate. The Phase 2 trial will compare the drug Berubicin’s response to established chemotherapy drug lomustine in treating glioblastoma (“GBM”), a fatal class of brain cancers generally considered incurable which usually only leaves patients about 15 months to live on average once they are diagnosed. Patient enrollment began last month across 35 clinical sites in the United States and CNS expects to expand the trial into western Europe during the coming year (https://ibn.fm/KEVIq). Once about 30 to 50 percent of the patients have reached the six-month point in the trial, CNS will conduct an interim non-binding futility analysis to obtain a snapshot of safety and secondary efficacy outcomes while enrollment otherwise continues. Berubicin, an anthracycline chemotherapy agent believed to be the first to successfully cross the blood-brain barrier to improve treatment capability, was the subject of a Phase 1 trial 15 years ago that resulted in the long-term survivability of one patient who achieved cancer-free status and continued in that condition during the most recent evaluation conducted in November. Among the other small pool of patients participating at that time, 44 percent saw their disease stabilize or improve, generating optimism for the drug’s potential (https://ibn.fm/gQBzo). CNS’s efforts have generated interest in the investment community that resulted in the company’s selection to be added to the Russell 2000 Index effective June 25, when the index undergoes its annual reconstitution, according to a news release announcement June 17 (https://ibn.fm/Pj9pQ). The reconstitution draws in the largest U.S. stocks each year and provides a benchmark measure consulted by investment managers and institutional investors for active investment strategies. The Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market, a subset of the Russell 3000 Index that represents about 10 percent of the total market capitalization of that index, according to the announcement. “We are pleased to meet this noteworthy milestone and be included in the Russell 2000 Index. As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (GBM), we believe this inclusion well-positions us to drive market awareness,” CNS Pharmaceuticals CEO John Climaco stated. “We are honored to be listed among our industry peers on what is considered to be a widely respected performance benchmark for small-cap companies. We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.” CNS has sublicensed Berubicin to Polish company WPD Pharmaceuticals, which will commence a similar Phase 2 clinical trial in Europe during 2H 2021. WPD also plans to conduct a clinical trial examining Berubicin’s safety for pediatric malignant glioma patients later in the year, which would be the first significant investigation of the therapy in these brain cancers in children (https://ibn.fm/VEY0J). WPD is also helping to advance GBM research by participating in an international consortium of industry experts researching the potential of nanoparticles in maximizing the efficiency of radiotherapy in X-ray dosing to end the recurrence of these high-grade tumors while preserving the adjacent healthy tissue (https://ibn.fm/p7Ydz). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP